Stelara Pediatric Crohn's Disease FDA Approval J&J Statement
May 02, 2026
May 02, 2026
RARITAN, New Jersey, May 2 -- Johnson and Johnson Innovative Medicine issued the following news release on May 1, 2026:
* * *
STELARA(R) Pediatric Crohn's Disease FDA Approval J&J Statement
On April 15, 2026, the U.S. Food and Drug Administration (FDA) approved STELARA(R)(ustekinumab) for the treatment of patients two years and older with moderately to severely active Crohn's disease (CD)./1
STELARA(R)(ustekinumab) is the only FDA . . .
* * *
STELARA(R) Pediatric Crohn's Disease FDA Approval J&J Statement
On April 15, 2026, the U.S. Food and Drug Administration (FDA) approved STELARA(R)(ustekinumab) for the treatment of patients two years and older with moderately to severely active Crohn's disease (CD)./1
STELARA(R)(ustekinumab) is the only FDA . . .